Jianbo Wang, M.D., Ph.D
Department of Genitourinary Medical Oncology, Division of Cancer Medicine
Present Title & Affiliation
Primary Appointment
Assistant Professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas
Dual/Joint/Adjunct Appointment
Assistant Professor, Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
Education & Training
Degree-Granting Education
| 2002 | Peking Union Medical University, Beijing, CN, Oncology, Ph.D |
| 1999 | Tongji Medical University, Wuhan, CN, Biochemistry, MMS |
| 1994 | Hubei University of Medicine, Shiyan, CN, Medicine, MD |
Postgraduate Training
| 2014-2017 | Clinical Fellowship, Hematology/Oncology, Baylor College of Medicine, Houston, Texas |
| 2011-2014 | Clinical Residency, Internal Medicine, St. Luke's Hospital, Chesterfield, Missouri |
Board Certifications
| 2017 | Hematology and Medical Oncology |
| 2014 | American Board of Internal Medicine |
| 2009 | ECFMG Certification |
Experience & Service
Administrative Appointments/Responsibilities
Patient Safety Quality Officer, Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, 2023 - Present
Other Appointments/Responsibilities
Assistant Professor, The University of Texas MD Anderson Cancer Center, Houston, TX, 2019 - Present
Institutional Committee Activities
Member, Penile Cancer Algorithm Working Group, 2024 - Present
Member, Hospital Throughput, 2024 - Present
Member, Institutional Review Board, 2023 - Present
Member, Spinal Cord Compression in Cancer Patients Algorithm Working Group, 2023 - Present
Member, Brain Mets Algorithm Working Group, 2022 - Present
Honors & Awards
| 2012 | Best Poster Award, St. Luke's Hospital |
| 1998 | Excellent Graduate Student of the Year, Tongji Medical University |
| 1994 | Scholarship Recipient, Hubei University of Medicine |
| 1993 | Scholarship Recipient, Hubei University of Medicine |
| 1992 | Scholarship Recipient, Hubei University of Medicine |
| 1991 | Scholarship Recipient, Hubei University of Medicine |
Professional Memberships
Selected Publications
Peer-Reviewed Articles
- Xiang JJ, Campbell MT, Tu SM, Araujo J, Nieto Y, Lin JK, Xiao L, Shah AY, Wang J. Doxorubicin, Paclitaxel, and Cisplatin (ATP) for Relapsed/Refractory Germ Cell Tumors. Clin Genitourin Cancer 22(6):102242, 2024. PMID: 39532049.
- Pizuorno Machado A, Shatila M, Liu C, Wang J, Altan M, Zhang HC, Thomas A, Wang Y. Immune-related adverse events after immune checkpoint inhibitor exposure in adult cancer patients with pre-existing autoimmune diseases. J Cancer Res Clin Oncol 149(9):6341-6350, 2023. e-Pub 2023. PMID: 36752908.
- Hollander B, Khurana S, Jacob JS, Altan M, Wang J, Zhao D, Varatharajalu K, Alasadi M, Thomas AS, Wang Y. Mesalamine and cholestyramine for immune checkpoint inhibitor-mediated diarrhea and colitis. J Cancer Res Clin Oncol 149(7):3637-3648, 2023. e-Pub 2022. PMID: 35972690.
- Mathew A, Shatila M, Lai Z, Tan D, Oliva ICG, Wang J, Alhalabi O, Zhang HC, Thomas A, Wang Y. Characteristics of appendicitis after immune checkpoint inhibitor therapy among cancer patients. J Cancer Res Clin Oncol 149(8):4591-4599, 2023. e-Pub 2022. PMID: 36163559.
- Tang C, Sherry AD, Haymaker C, Bathala T, Liu S, Fellman B, Cohen L, Aparicio A, Zurita AJ, Reuben A, Marmonti E, Chun SG, Reddy JP, Ghia A, McGuire S, Efstathiou E, Wang J, Wang J, Pilie P, Kovitz C, Du W, Simiele SJ, Kumar R, Borghero Y, Shi Z, Chapin B, Gomez D, Wistuba I, Corn PG. Addition of Metastasis-Directed Therapy to Intermittent Hormone Therapy for Oligometastatic Prostate Cancer: The EXTEND Phase 2 Randomized Clinical Trial. JAMA Oncol 9(6):825-834, 2023. e-Pub 2023. PMID: 37022702.
- Vasavada S, Panneerselvam K, Amin R, Varatharajalu K, Okhuysen PC, Oliva ICG, Wang J, Grivas P, Thomas AS, Wang Y. Clostridioides difficile infection in cancer patients receiving immune checkpoint inhibitors. Ann Gastroenterol 35(4):393-399, 2022. e-Pub 2022. PMID: 35784625.
- Wang J, Tawbi HA. Emergent immunotherapy approaches for brain metastases. Neurooncol Adv 3(Suppl 5):V43-V51, 2021. PMID: None.
- Gao J, Navai N, Alhalabi O, Siefker-Radtke A, Campbell M, Slack Tidwell R, Guo CC, Kamat AM, Matin S, Araujo JC, Shah AY, Msaouel P, Corn P, Wang J, Papadopoulos JN, Yadav SS, Blando JM, Duan F, Basu S, Liu W, Shen Y, Zhang Y, Macaluso MD, Wang Y, Chen J, Zhang J, Futreal A, Dinney C, Allison JP, Goswami A, Sharma P. Neoadjuvant combination PD-L1 plus CTLA-4 blockade in patients with cisplatin2 ineligible operable high-risk urothelial carcinoma. Nature Medicine, 2021. PMID: None.
- Alhalabi O, Hasanov E, Wilson NR, Araujo J, Wang J, Campbell MT, Goswami S, Shah AY, Gao J, Msaouel P, Tannir NM. Outcomes of patients with intermediate-risk or poor-risk metastatic renal cell carcinoma who received their first cycle of nivolumab and ipilimumab in the hospital because of symptomatic disease: The MD Anderson Cancer Center experience. Int J Cancer 149(2):387-393, 2021. e-Pub 2021. PMID: 33739450.
- Zou, F, Abu-Sbeih, H, Ma, W, Peng, Y, Qiao, W, Wang, J, Shah, AY, Glitza, IC, Piha-Paul, SA, Thompson, JA, Zhang, HC, Thomas, AS, Wang, Y. Association of chronic immune-mediated diarrhea and colitis with favorable cancer response. JNCCN Journal of the National Comprehensive Cancer Network 19(6):700-708, 2021. PMID: 33316767.
- Spetsieris N, Boukovala M, Weldon JA, Tsikkinis A, Hoang A, Aparicio A, Tu SM, Araujo JC, Zurita AJ, Corn PG, Pagliaro L, Kim J, Wang J, Subudhi SK, Tannir NM, Logothetis CJ, Troncoso P, Wang X, Wen S, Efstathiou E. A Phase 2 Trial of Abiraterone Followed by Randomization to Addition of Dasatinib or Sunitinib in Men With Metastatic Castration-Resistant Prostate Cancer. Clin Genitourin Cancer 19(1):22-31.e5, 2021. PMID: None.
- Gao J, Navai N, Alhalabi O, Siefker-Radtke A, Campbell MT, Tidwell RS, Guo CC, Kamat AM, Matin SF, Araujo JC, Shah AY, Msaouel P, Corn P, Wang J, Papadopoulos JN, Yadav SS, Blando JM, Duan F, Basu S, Liu W, Shen Y, Zhang Y, Macaluso MD, Wang Y, Chen J, Zhang J, Futreal A, Dinney C, Allison JP, Goswami S, Sharma P. Neoadjuvant PD-L1 plus CTLA-4 blockade in patients with cisplatin-ineligible operable high-risk urothelial carcinoma. Nat Med 26(12):1845-1851, 2020. PMID: 33046869.
- Zou F, Abu-Sbeih H, Ma W, Peng Y, Qiao W, Wang J, Shah AY, Glitza Oliva IC, Piha-Paul SA, Thompson JA, Zhang HC, Thomas AS, Wang Y. Association of Chronic Immune-Mediated Diarrhea and Colitis With Favorable Cancer Response. J Natl Compr Canc Netw 19(6):700-708, 2020. PMID: None.
- Wang J, Zhang K, Grabowska D, Li A, Dong Y, Day R, Humphrey P, Lewis J, Kladney RD, Arbeit JM, Weber JD, Chung CH, Michel LS. Loss of Trop2 promotes carcinogenesis and features of epithelial to mesenchymal transition in squamous cell carcinoma. Mol Cancer Res 9(12):1686-95, 2011. e-Pub 2011. PMID: 21970857.
- Saporita AJ, Chang HC, Winkeler CL, Apicelli AJ, Kladney RD, Wang J, Townsend RR, Michel LS, Weber JD. RNA helicase DDX5 is a p53-independent target of ARF that participates in ribosome biogenesis. Cancer Res 71(21):6708-17, 2011. e-Pub 2011. PMID: 21937682.
- Dong Y, Li A, Wang J, Weber JD, Michel LS. Synthetic lethality through combined Notch-epidermal growth factor receptor pathway inhibition in basal-like breast cancer. Cancer Res 70(13):5465-74, 2010. e-Pub 2010. PMID: 20570903.
- Wang J, Day R, Dong Y, Weintraub SJ, Michel L. Identification of Trop-2 as an oncogene and an attractive therapeutic target in colon cancers. Mol Cancer Ther 7(2):280-5, 2008. PMID: 18281513.
- Yueying W, Jianbo W, Hailin L, Huaijing T, Liping G, Shih-Hsin L. ECRG1, a novel esophageal gene, cloned and identified from human esophagus and its inhibition effect on tumors. Carcinogenesis 29(1):157-60, 2008. e-Pub 2007. PMID: 17971341.
- Zhao N, Wang J, Cui Y, Guo L, Lu SH. Induction of G1 cell cycle arrest and P15INK4b expression by ECRG1 through interaction with Miz-1. J Cell Biochem 92(1):65-76, 2004. PMID: 15095404.
- Cui YP, Wang JB, Zhang XY, Bi MX, Guo LP, Lu SH. Using yeast two-hybrid system to identify ECRG2 associated proteins and their possible interactions with ECRG2 gene. World J Gastroenterol 9(9):1892-6, 2003. PMID: 12970870.
- Cui Y, Wang J, Zhang X, Lang R, Bi M, Guo L, Lu SH. ECRG2, a novel candidate of tumor suppressor gene in the esophageal carcinoma, interacts directly with metallothionein 2A and links to apoptosis. Biochem Biophys Res Commun 302(4):904-15, 2003. PMID: 12646258.
- Wang J, Fan Y, Guo L, Lu S. [Search for interacting proteins of esophageal cancer related gene-1 encoded protein through the yeast two-hybrid system]. Zhonghua Zhong Liu Za Zhi 24(3):219-21, 2002. PMID: 12515610.
- Wang J, Wang C, Liu Z, Tian J, Qu S. The modification on lipoprotein labeling method with DiI. Chinese Journal of Arteriosclerosis 10(1):65-68, 2002. PMID: None.
- Liu R, QU S, Wang J, Guo J, Zhou H. IL-6 and B7-1 costimulation cooperate in the induction of T lymphocytes activation in vitro. Chinese Journal of Immunology 16(2):96-98, 2000. PMID: None.
- Shen Q, Wang J, Liu Z, Deng Y, Feng Z. Cloning of Chinese very low density lipoprotein receptor gene and its expression in CHO cells. Chinese Journal of Arteriosclerosis 8(3):189-192, 2000. PMID: None.
- Liu R, Wang J, Qu S, Zhou H. Antitumor effect of mouse B16 melanoma cells transfected with mB7-1. Chinese Journal of Clinical Oncology 26(12):924-927, 1999. PMID: None.
- Qu S, Liu R, Wang Y, Wang J. Preliminary study on the cooperation of IL-6 and mB7-1 in the induction of effective anti-tumor immunity in vitro. Journal of Tongji Medical University 19(2):86-89, 1999. PMID: None.
- Qu S, Liu R, Wang J, Wang Y. Experimental study on the anti-tumor effect of mouse B7-1 gene. Journal of Tongji Medical University 19(1):10-14, 1999. PMID: None.
Other Articles
- Wang J, Kuperman DI A blood-making lung mass. Ann Hematol 92(11):1559-60, 2013. PMID: 23525685.
Abstracts
- Alhalabi O, Wilson N, Xiao L, Naval N, Kamat A, Shah A, Araujo J, b|Wang J, Goswami S, Gao J, Wang J, Guo C, Czerniak B, Corn P, Logothetis C, Dinney C, Campbell M, Tannir N, Siefker-Radtke A. Factors associated with improved outcomes in surgically resectable small cell urothelial cancer (SCUC). Journal of Clinical Oncology, 2022. PMID: None.
- Alhalabi O, Wilson N, Ajufo H, Lehner M, Hasanov E, Campbell M, Shah A, Wang J, Jonasch E, Araujo J, b|Wang J, Gao J, Goswami S, Msaouel P, Tannir N. Safety and differential clinical activity of nivolumab plus ipilimumab (nivo-ipi) in patients (pts) with non-clear cell renal cell carcinoma (nccRCC). Journal of Clinical Oncology, 2022. PMID: None.
- Wang J. Characterization of metastatic spinal cord compression from prostate cancer. Journal of Clinical Oncology 38:6_suppl, 248-248, 2020. PMID: None.
Book Chapters
- Wang J, Hayes TG. Early Stage Prostate Cancer: Controversies in Management. In: Handbook of Prostate Cancer and Other GU Malignancies. None. None, 2017.
Patient Reviews
CV information above last modified November 19, 2024